Morial Convention Center

Spectrum Pharmaceuticals Announces ZEVALIN® Data Presentations at the 51st Annual Meeting of the American Society of Hematology in New Orleans

Business Wire (Free subscription) | yesterday

IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a commercial stage biotechnology company with a primary focus in oncology, today announced that clinical data on ZEVALIN will be presented at the 51st Annual Meeting of the American Society of Hematology (ASH), being held December 5-8, 2009 at the Ernest N. Morial Convention Center in New Orleans,...

51st Annual Meeting of the American Society of Hematology Will Highlight Research and Policy Changes Affecting Medical Practice and Patient Care

PR News Wire (Free subscription) | yesterday

NEW ORLEANS, Dec. 1 /PRNewswire-USNewswire/ -- The American Society of Hematology (ASH), the world's largest professional association of blood specialists, expects more than 20,000 attendees at the 51st ASH Annual Meeting from December 5-8, 2009, at the Ernest N. Morial Convention Center in New Orleans, LA. The meeting will showcase the latest research and treatments for blood...

• ASH meeting will highlight research and policy changes affecting medical practice and patient care - Eurekalert
• Spectrum Pharmaceuticals Announces ZEVALIN® Data Presentations at the 51st Annual Meeting of the American Society of Hematology in New Orleans - Business Wire
• See the 5 articles on the same subject

51st Annual Meeting of the American Society of Hematology Will Highlight Research and Policy Changes Affecting Medical Practice and Patient Care

PR News Wire (Free subscription) | yesterday

NEW ORLEANS, Dec. 1 /PRNewswire-USNewswire/ -- The American Society of Hematology (ASH), the world's largest professional association of blood specialists, expects more than 20,000 attendees at the 51st ASH Annual Meeting from December 5-8, 2009, at the Ernest N. Morial Convention Center in New Orleans, LA. The meeting will showcase the latest research and treatments for blood...

• ASH meeting will highlight research and policy changes affecting medical practice and patient care - Eurekalert

Acceleron Pharma to Present Data on ACE-011 and ACE-536 at the 51st Annual Meeting of the American Society of Hematology

Business Wire (Free subscription) | yesterday

... be presented at the 51st Annual Meeting of the American Society of Hematology at the Ernest N. Morial Convention Center in New Orleans, Louis

ASH meeting will highlight research and policy changes affecting medical practice and patient care

Eurekalert (Free subscription) | yesterday

( American Society of Hematology ) The American Society of Hematology, the world's largest professional association of blood specialists, expects more than 20,000 attendees at the 51st ASH Annual Meeting from Dec. 5-8, 2009, at the Ernest N. Morial Convention Center in New Orleans. The meeting will showcase the latest research and treatments for blood disorders.

Cytokinetics, Inc.: Cytokinetics Announces Clinical Trial Data Regarding SB-743921 to Be Presented at the 2009 American Society of Hematology Annual Meeting and Exposition

Market Wire (Free subscription) | 30/11/2009

SOUTH SAN FRANCISCO, CA (MARKET WIRE) Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that an abstract summarizing clinical trial data regarding SB-743921 is scheduled to be presented as a poster presentation at the 2009 American Society of Hematology (ASH) Annual Meeting and Exposition to be held December 5-8, 2009 at the Ernest N. Morial Convention Center in New Orleans,...

13 Biotechs to Watch for at Hematology Conference

SeekingAlpha.com (Free subscription) | 30/11/2009

Michael Becker submits: The 51 st American Society of Hematology [ASH] Annual Meeting will take place December 5-8, 2009, at the Ernest N. Morial Convention Center in New Orleans, LA. This is the premier event for the hematology industry, attracting more than 20,000 hematologists and other health-care professionals. In this regard, Celgene Corporation ( CELG ) recently announced...

Gloucester Pharmaceuticals To Present Positive Results From Multiple Studies Of ISTODAX(R) At The ASH Annual Meeting

Medical News Today (Free subscription) | 26/11/2009

Gloucester Pharmaceuticals announced multiple presentations from clinical and preclinical studies of ISTODAX® (romidepsin) at the upcoming 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, Louisiana, at the Ernest N. Morial Convention Center, December 5 - 8, 2009. ISTODAX, a novel histone deacetylase (HDAC) inhibitor, was recently approved...

Gloucester Pharmaceuticals to Present Positive Results from Multiple Studies of ISTODAX® at the ASH Annual Meeting

Business Wire (Free subscription) | 24/11/2009

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gloucester Pharmaceuticals today announced multiple presentations from clinical and preclinical studies of ISTODAX® (romidepsin) at the upcoming 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, Louisiana, at the Ernest N. Morial Convention Center, December 5 – 8, 2009. ISTODAX, a novel histone deacetylase...